KATHLEEN BURNS: Open Payments
NPI 1750794202 · DUARTE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$50,005 in 64 payments from 11 companies in 2025. Trend: 2023 $31,721 · 2024 $38,254 · 2025 $50,005
Speaker / faculty: $39,238Travel & lodging: $5,659Speaker / faculty: $2,750Food & beverage: $1,558Consulting: $800
| Company | Payments | Amount |
|---|---|---|
| Sumitomo Pharma America, Inc. | 19 | $36,082 |
| PFIZER INC. | 12 | $6,483 |
| Exelixis Inc. | 15 | $4,617 |
| AstraZeneca Pharmaceuticals LP | 3 | $1,827 |
| Eisai Inc. | 1 | $560 |
| Janssen Biotech, Inc. | 6 | $152 |
| PROGENICS PHARMACEUTICALS, INC. | 2 | $138 |
| Novartis Pharmaceuticals Corporation | 3 | $85 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $25 |
| Astellas Pharma US Inc | 1 | $23 |
Products named: ORGOVYX, CABOMETYX, XTANDI, TALZENNA, LYNPARZA, Lenvima, ERLEADA, PYLARIFY.
Industry payments across CA — which companies pay providers there.
